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small peptide Ligands for targeting 
eGFR in triple Negative Breast 
Cancer Cells
Hanieh Hossein-Nejad-Ariani, emad Althagafi & Kamaljit Kaur
The efficacy of chemotherapy for cancer treatment can be increased by targeted drug delivery to 
the cancer cells. This is particularly important for triple negative breast cancer (TNBC) for which 
chemotherapy is a major form of treatment. Here we designed and screened a library of 30 peptides 
starting with a previously reported epidermal growth factor receptor (EGFR) targeting peptide GE11 
(YHWYGYTPQNVI). A direct peptide array-whole cell binding assay, where the peptides are conjugated 
to a cellulose membrane, was used to identify four peptides with enhanced binding to TNBC cells. 
Next, the four peptides were synthesized as FITC-labelled soluble peptides to study their direct uptake 
by TNBC cells using flow cytometry. The results showed that peptide analogue 22 had several fold 
higher uptake by the TNBC cells compared to the lead peptide GE11. The specific uptake of the peptide 
analogue 22 was confirmed by competition experiment using pure EGF protein. Further, peptide 22 
showed dose dependent uptake by the TNBC MDA-MB-231 cells (105) with uptake saturating at around 
2 μM peptide concentration. Thus, peptide 22 is a promising EGFR specific TNBC cell binding peptide 
that can be conjugated directly to a chemotherapeutic drug or to nanoparticles for targeted drug 
delivery to enhance the efficacy of chemotherapy for TNBC treatment.
Triple negative breast cancer (TNBC) is an important subtype of breast cancer as it is more aggressive than other 
subtypes and has poor prognosis1–4. TNBC is characterized as a breast cancer phenotype that is estrogen recep-
tor (ER) negative, progesterone receptor (PR) negative, and is without the overexpression of human epidermal 
growth factor receptor 2 (HER2), and hence is called the “triple-negative” phenotype2. TNBC is more common 
in younger women, premenopausal African American women, and women of lower socioeconomic status (SES) 
when compared to other subtypes. Diagnosis of TNBC usually happens at the more advanced stage of the disease 
and it usually leads to death within the first five years of diagnosis. Additionally, in TNBC, high grade rapidly 
growing tumors are poorly differentiated and metastasis tends to occur in soft tissues including lungs and brain 
rather than in bone4. Chemotherapy is a major way to treat TNBC. However it has been difficult to target chemo-
therapy to TNBC due to the lack of well-defined molecular targets2,5,6.
Peptide 1 (or GE11, Table 1) is a dodecapeptide that binds specifically to epidermal growth factor receptor 
(EGFR or ErbB1) overexpressed in a number of tumors of epithelial origin including breast cancer, and is being 
used as a cancer cell targeting peptide7–10. EGFR has been suggested to play an important role in TNBC11,12. 
Several TNBC cell lines, like MDA-MB-468 and MDA-MB-231, show high expression levels of EGFR13,14. 
Although therapeutic monoclonal antibodies like cetuximab and tyrosine kinase inhibitors like lapatinib have 
not shown much success in clinical trials for TNBC patients, several EGFR-targeted antibody-drug conju-
gates (ADCs) show great potential for TNBC treatment and are currently undergoing clinical trials for TNBC 
patients11. Similarly peptide-drug conjugates can be designed for targeting EGFR in TNBC. The cancer cell target-
ing peptides are not therapeutic like antibodies, but have several advantages as targeting ligands over antibodies 
such as they can be easily synthesized, are more economical, can be designed as stable analogues, and display low 
immunogenicity.
Several peptides that target breast cancer cells have been engineered for enhanced specificity and proteolytic 
stability for clinical applications15–17. Peptides like RGD18, NGR19–21, and p160 (VPWMEPAYQRFL)22–24 target 
a number of different receptors such as integrin, aminopeptidase N (or CD13) and keratin 1, respectively, over-
expressed by breast cancer cells. A cyclic analogue of peptide p160, N- to C terminal cyclized WXEAAYQkFL 
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(where k is D-lysine), was recently reported that preferentially accumulates in tumor after injection in mice car-
rying orthotopic breast MDA-MB-231 tumors25. Similarly, peptide 1 is a good candidate peptide for breast cancer 
targeting as it binds EGFR, and can be engineered for proteolytically stability and specific targeting of TNBC 
cells. Peptide 1 was identified by screening a phage display peptide library against purified human EGFR protein8. 
The peptide is internalized by cells overexpressing EGFR and when delivered i.v. in mice it accumulates in EGFR 
overexpressing tumor xenografts. Peptide 1 has been used as the targeting ligand for delivery of genes using poly-
ethylenimine (PEI) polyplexes and antisense oligonucleotide nanoparticles8,26. A number of studies have explored 
peptide 1 as a targeting ligand in nanoparticles to treat cancers including breast and ovarian malignant cells27–31.
Here we have designed a synthetic peptide library of 29 analogues of peptide 1 (GE11)8 with an aim to target 
EGFR specifically in TNBC cells (Table 1). The library was synthesized directly on cellulose membrane where the 
peptides remain covalently conjugated to the membrane. The library was screened against TNBC cells by incubat-
ing the membrane with different cells followed by labeling the bound cells with a fluorescent dye. Peptides showing 
highest relative fluorescence compared to the lead peptide (peptide 1) were selected from the whole cell-peptide 
binding assay, and were individually synthesized as well as their uptake in normal and TNBC cells was compared. 
Peptide 4 (or p160) reported previously to target breast cancer cells was used as a positive control peptide23–25. 
Several new analogues of peptide 1 with higher binding (using whole cell-peptide binding assay) and uptake (using 
flow cytometry) to TNBC were identified. The new analogues of peptide 1 that target EGFR and specifically bind 
TNBC cells can be used for targeted delivery of chemotherapeutics like doxorubicin for TNBC treatment.
Results and Discussion
Peptide Array Synthesis. A peptide array consisting of 30 peptides in duplicates (60 spots) was synthesized 
on functionalized cellulose membrane (amino-PEG500) using automated spot synthesis ResPep SL apparatus. The 
free amino functional group present on the surface of the membrane was used to covalently couple the first amino 
acid, and thereafter the remaining amino acids were coupled sequentially to complete the sequences. Peptide 
array was synthesized using 96 spot mode (12 columns and 8 rows). Each peptide was synthesized in duplicates 
and a spot was skipped in order to separate from the next peptide sequence.
Peptide# Sequence
Relative Cell Adhesion
MDA-MB-468 MDA-MB-231 MDA-MB-436 MCF-10A
1 YHWYGYTPQNVI 1.0 1.0 1.0 1.0
2 WQTNYIHPYVYG 1.1 1.2 1.1 1.0
3 YGPWYNHYITQV 1.0 1.1 1.1 1.0
4 VPWXEPAYQRFL 1.1 1.3 1.1 1.2
5 WXEAAYQRFL 1.3 1.7 1.8 1.7
6 AHWYGYTPQNVI 1.2 1.3 1.0 1.1
7 YAWYGYTPQNVI 1.1 1.1 1.0 1.0
8 YHAYGYTPQNVI 0.8 1.0 0.9 0.9
9 YHWAGYTPQNVI 1.3 1.4 1.2 1.0
10 YHWYAYTPQNVI 1.3 1.5 1.2 1.1
11 YHWYGATPQNVI 1.2 1.3 1.0 1.0
12 YHWYGYAPQNVI 1.0 1.3 1.0 1.1
13 YHWYGYTAQNVI 1.3 1.5 1.1 1.1
14 YHWYGYTPANVI 1.4 1.7 1.2 1.2
15 YHWYGYTPQAVI 1.2 1.6 0.9 1.1
16 YHWYGYTPQNAI 1.1 1.4 1.0 1.2
17 YHWYGYTPQNVA 1.4 1.6 1.2 1.2
18 YHWYGYTPQNV 1.4 1.9 1.3 1.2
19 YHWYGYTPQN 1.3 2.0 1.1 1.1
20 HWYGYTPQNVI 1.2 1.5 1.0 1.2
21 WYGYTPQNVI 1.4 1.9 1.0 1.2
22 YHWYGYTPENVI 1.6 2.6 1.3 1.2
23 YHWYGYTPQDVI 1.6 2.8 1.0 1.4
24 YKWYGYTPQNVI 1.1 1.4 1.0 1.0
25 YRWYGYTPQNVI 1.4 1.9 1.0 1.2
26 YHWYGYTPKNVI 1.3 1.6 1.0 0.8
27 YHWYGYTPQKVI 1.2 1.8 1.0 1.0
28 FHWYGYTPQNVI 1.2 1.5 0.8 1.2
29 YHWFGYTPQNVI 1.2 1.7 1.1 1.1
30 YHWYGFTPQNVI 1.3 1.5 0.9 1.0
Table 1. Designed peptide GE11 (or peptide 1) library and the relative cell adhesion ratio of the peptides. The 
letter X in the peptide sequence represents the amino acid norleucine (Nle).
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Peptide Library. Peptide 1 (GE11, Table 1) is a 12-mer peptide rich in hydrophobic aromatic amino acids 
(three tyrosine’s and one tryptophan). Using previous strategy21,32, we designed a library consisting of 
GE11-derived peptide sequences. The library of 30 peptides includes negative (2 and 3, scrambled) and positive 
(4 or peptide p160 and 5 or peptide 18 from a previous study)33 control sequences. There were also sequences 
with alanine scan (peptides 6–17), C-terminus truncated sequences (18–19), N-terminus truncated sequences 
(20–21), and negatively (22–23) and positively (24–27) charged analogues. Finally the peptide library also had 
sequences with Y to F substitutions (28–30).
Peptide array on the cellulose membrane was used to evaluate the binding of each peptide to different cell lines. 
The amino functionalized cellulose membrane provided by Intavis is acid hardened providing high stability at pH 
range from 1–14, permitting its use in acidic or basic conditions while maintaining membrane integrity. The PEG 
linker on membrane surface functions as a hydrophilic spacer between the peptide and the solid surface (mem-
brane) reducing background signal. Cell lines were carefully selected for screening peptides as our goal here is to 
screen peptides with high binding/uptake by the TNBC cells. Our lead peptide, peptide 1 (or GE11) targets and 
binds EGFR. EGFR is overexpressed by a number of TNBC cells such as MDA-MB-468 (obtained from primary 
tumor source) and MDA-MB-231 (from metastasis cancer tissue)13,14. While other TNBC cells like MDA-MB-436 
(obtained from metastasis cancer tissue) are known to express low levels of EGFR. Non-tumorigenic epithelial 
MCF10A and MCF12A cells derived from the breast tissue also express low levels of EGFR14,34. We selected two 
TNBC cell lines with relatively high expression of EGFR expression (MDA-MB-468/231) and a TNBC cell line 
with low level of EGFR expression (MDA-MB-436) for the peptide array screening experiments. In addition, non- 
tumorigenic cell line, MCF-10A was used for comparison. These four cell lines were allowed to bind the mem-
brane by seeding the cells on the membrane and the bound cells were labeled with a fluorescent dye CyQUANT.
Peptide Library Screening. To screen the library and identify high binding peptides to TNBC cells, the 
relative cell adhesion was monitored by comparing the fluorescence of cells (cancer or non-cancerous) bound to 
wild type peptide 1 (Table 1). Peptides 22 and 23 displayed highest affinity (up to 2.8-fold compared to peptide 1) 
to the three TNBC cell lines. These two peptides with Q9E and N10D substitutions, respectively, are negatively 
charged (net charge −1). Two other peptides that also showed high affinity were peptides 26 and 27. Here again 
the two same amino acids (Q9 and N10) were substituted, however, with positively charged lysine. Analysis of the 
alanine scan showed that substitution of these two residues (Q9 and N10) with alanine (especially peptide 14 with 
Q9A substitution) also gives higher binding to cancer cells. These results suggest that substitution of Q9 with a 
negatively charged glutamic acid (E) leads to highest cancer cell binding. In addition, alanine scan suggested that 
W3 is important for cancer cell binding as substitution of this residue with alanine led to decrease in relative cell 
adhesion ratio (0.8–1.0). The positive control peptide 5 showed higher binding to TNBC cells compared to pep-
tide 1 (1.3–1.8-fold), however, positive control peptide 4 did not show much improvement in binding based on 
the peptide array-whole cell binding assay. Based on these results, four peptides 22, 23, 26, and 27 that displayed 
highest binding to the TNBC cells and did not show any substantial increase in affinity for the non-cancerous cells 
(MCF10A) were selected for cell uptake studies.
In Vitro Cell Uptake of Soluble (Free) Peptides. Flow cytometry was employed to determine the cellular 
uptake of selected six peptides (1, 4, 22, 23, 26, and 27). As opposed to the membrane bound (conjugated) pep-
tide in library screening, the peptides used here were soluble (or free) FITC-labeled peptides. Peptides were labe-
led with FITC in the N-terminal and a β-alanine residue was used as a spacer between the FITC and the peptide 
sequence. The same three TNBC cells lines (MDA-MB-468, MDA-MB-231 and MDA-MB-436) used for peptide 
array screening were used here as well. Peptides 1 and 4 were used as controls. Peptide 1 is the lead EGFR binding 
peptide, whereas, peptide 4 binds keratin 1. Peptide 4 was included in this experiment to compare the uptake of 
this keratin 1 binding peptide with the EGFR binding peptides. Peptides 22, 23, 26, and 27 were identified as the 
best EGFR binding peptides from the library screening.
Figure 1 shows histograms and the mean fluorescence intensity (MFI) values for the three TNBC cell lines 
treated with six FITC-labeled peptides. Cell population treated with peptides 4, 22, 23, 26, and 27 showed signif-
icant FITC fluorescence in MDA-MB-468 and MDA-MB-231 when compared with cells treated with media only 
or treated with peptide 1. Peptide 4 showed much higher uptake (MFI 23741) compared to the EGFR binding 
peptides (MFI 8384 or less). Among the new EGFR binding peptides, peptide 22 showed the highest uptake by the 
TNBC cells. In addition, the uptake of peptide 22 to MDA-MB-468 and MDA-MB-231 cells improved substan-
tially with 123-fold and 47-fold higher affinity, respectively, compared to peptide 1. The peptides showed highest 
uptake by the MDA-MB-468 cells followed by MDA-MB-231, and the lowest uptake was for MDA-MB-436 cells. 
Interestingly this is also the order of EGFR expression that is reported for these three cell lines with MDA-MB-468 
showing highest level of EGFR expression13,14. The uptake of peptides 26 and 27 is only slightly less compared to 
peptide 22 even though these peptides have a substitution of a positively charged residue (K) for Q9 or N10 as 
opposed to negatively charged residue (E) for Q9 in peptide 22 (Fig. 1 table). It is anticipated that these peptide 
binds to the same site on EGFR as the native ligand EGF, and comparison of the amino acid sequence of these 
peptides and EGF shows that E and R may be preferred residues at positions 9 and 10 (vide infra).
In addition, it is notable that the uptake of the peptides by the cells is affected by the presence of free 
C-terminal carboxylic group, because the membrane bound peptides without free C-terminal carboxylic group 
showed less binding affinity to the cells compared to the soluble (or free) FITC labeled peptides which contain 
the free C-terminal carboxylic group. For instance peptide 22 showed only 2–3 fold improvement compared 
to peptide 1 (Table 1) using the peptide array-whole cell binding assay, whereas the uptake of peptide 22 by 
MDA-MB-468/231 cells is 50–123 fold compared to peptide 1 when evaluated using soluble (free) peptides in in 
vitro uptake using flow cytometry (Fig. 1).
www.nature.com/scientificreports/
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Specific Uptake of Peptides by TNBC Cells. The specific uptake of peptides 1 and 22 was evaluated using 
a competitive assay. First, MDA-MB-231 cells were incubated with peptide FITC-1 in the presence and absence 
of excess EGF protein (20-fold). The cells showed about 17% decrease in fluorescence when incubated in the 
presence of EFG protein (Fig. 2). Next, the cells were incubated with peptide FITC-1 with or without excess unla-
beled peptide 1 (100-fold). A similar decease in fluorescence (19.5% decrease) was observed when the cells were 
incubated with excess unlabeled peptide 1 suggesting multiple binding modes for peptide 1 on MDA-MB-231 
cells. The competition experiment was also repeated with peptide 22 in the presence and absence of EGF protein. 
As shown in Fig. 3, the FITC positive cells reduced significantly from 99% to 2% (97% decrease) when the cells 
were incubated with peptide 22 in the presence of 20-fold excess EGF protein. The decrease in FITC positive 
cells was much higher for peptide 22 (97%) compared to peptide 1 (17%) suggesting that peptide 22 has higher 
specific binding to EGFR than peptide 1. These results support our conjecture that the newly designed peptide 22 
targets and binds EGFR, likely at the same site as EGF protein, and the binding or uptake can be reduced when 
the receptor is blocked with excess EGF.
Further we incubated a fixed number of MDA-MB-231 cells (105) with different concentrations of peptide 22 
(0–6 μM). The results showed that uptake was concentration independent in the range 1–6 μM (Fig. S1) suggest-
ing that half saturation is below 1 μM. A direct interaction between the peptide and the isolated protein (EGFR) 
is required to confirm this specificity as well as the binding affinity. Previously Li et al. reported a Kd of 22 nM for 
peptide 1 binding to EGFR where the authors studied direct binding of the peptide to the pure EGFR protein8.
Peptide 22 Structure. As shown in Fig. 4a, the main difference in the chemical structures of peptides 1 and 
22 is the presence of a negatively charged carboxylate in the side chain of glutamic acid of peptide 22, whereas 
in peptide 1 this residue is uncharged (Gln). We next compared the sequence of peptide 22 with the EGF pro-
tein to understand the enhanced binding of peptide 22 to EGFR compared to peptide 1. We found a region in 
EGF that may have structural similarity to peptide 22 (Fig. 4b). There is low sequence homology between the 
two sequences (peptide 22 and 12-residue region of EGF), however, based on the predicted secondary struc-
ture of peptide 22 and x-ray protein structure of EGF35 it seems that these two have high structural similarity. 
Notably, this region of EGF (32–43) contains several residues that are involved in direct interaction with the 
EGFR based on the site-directed mutagenesis studies as well as the crystal structure of human EGF in complex 
with EGFR extracellular region36. Residues 32–43 of EGF loop to form a cyclic structure (Fig. 4c) and secondary 
structure prediction37,38 of peptide 22 suggests that it consists of sheet and coil structures with a turn at P8 and 
E9 (Fig. 4d). Further, a homology based energy minimized structure for peptide 22 was obtained that shows 
structural similarly between residues 32–43 of EGF and peptide 22 (Fig. 4e). This structure displays that peptide 
22 has a turn at E9 near the C-terminus and the peptide C-terminus coils back toward the N-terminus. These 
results suggest that a cyclic analogue of peptide 22 may give a high affinity EGFR binding peptide which should 
Figure 1. Uptake of the FITC-labeled peptides by triple negative breast cancer cells MDA-MB-468, 
MDA-MB-231, and MDA-MB-436. Cells (105 or 106/well) were treated with peptides (1 µM) and incubated for 
30 min at 37 °C before analysis by FACS. The experiments were repeated twice and done in duplicates for each 
sample. Control group was treated with DMSO (5%). The table lists the mean fluorescence intensity (MFI) for 
the FITC positive cells for three independent experiments ± SD.
www.nature.com/scientificreports/
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also have enhanced proteolytic stability. Such cyclic analogue of peptide 22 need to be tested. Peptide 22 shows 
short half-life (~1 hour) when incubated with human serum most likely due to proteolysis (data not shown). 
Previously we showed that a cyclic analogue (cyclic WXEAAYQkFL) of breast cancer targeting peptide 18–4 
Figure 2. Competitive uptake of peptide 1 by FACS analysis. Fluorescence was measured for the MDA-MB-231 
cells (105 cells) alone or for the cells after incubation with peptide FITC-1 (1 μM), peptide FITC-1 in the 
presence of 20-fold excess EGF protein (20 μM) or peptide FITC-1 in the presence of 100-fold excess unlabeled 
peptide 1 (100 μM). Also shown is the bar diagram for the percent of FITC positive cells in the absence and 
presence of excess free peptide 1 or EGF. Experiment was done in duplicates for each sample ± SD. The 
asteristik (*) denotes statistically significant deference (p < 0.05). Each well of cells was read twice in the FACS 
instrument. 10,000 cells were read.
Figure 3. Competitive uptake of peptide 22 by FACS analysis. Fluorescence was measured for the 
MDA-MB-231 cells (105 cells) alone or for the cells after incubation with peptide FITC-22 (1 μM) or peptide 
FITC-22 in the presence of 20-fold excess EGF protein (20 μM). Experiments were done in duplicates for each 
sample. 10,000 cells were read.
www.nature.com/scientificreports/
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(WxEAAYQrFL, where lower case x is D-norleucine or D-Nle) was stable toward proteolytic degradation as well 
as displayed higher uptake by the breast cancer cells compared to the linear peptide25.
Concluding Remarks
Four analogues (22, 23, 26, and 27) of peptide 1 (YHWYGYTPQNVI) with high uptake by TNBC cells that 
express high levels of EGFR are reported in the current investigation. Among these four new analogues, peptide 
22 showed the highest uptake by the TNBC cells. For both MDA-MB-468 and MDA-MB-231 cells, a 123-fold and 
47-fold increase, respectively, in uptake of soluble FITC-labeled peptide 22 was observed compared to the lead 
peptide 1. Both these cells lines (MDA-MB-468 and MDA-MB-231) are reported to express high levels of EGFR. 
Mueller et al. used lysates of breast cancer cell lines to obtain proteins which were separated by SDS-PAGE and 
immunoblotted with anti-EGFR to show overexpression of EGFR by these TNBC cell lines14. The specific binding 
and uptake of peptide 22 by EGFR in TNBC cells is further confirmed by competition assay where the uptake of 
22 (99%) was reduced to 2% when the cells were incubated in the presence of excess EGF protein.
The comparison of peptide 22 sequence with a portion of EGF protein suggests that there may be structural 
similarity further supporting peptide’s specificity for EGFR. We are currently investigating an N- to C-terminal 
cyclic analogue of peptide 22. Our preliminary results for the stability of peptides 1 and 22 in the presence of 
human serum show that these peptide have a short half-life (data not shown here). Our conjecture is that cycli-
zation of peptide 22 will impart proteolytic stability while maintaining specificity for EGFR for its use in TNBC 
Figure 4. (a) Chemical structure of peptide 1 (GE11) and peptide analogue 22. (b) Amino acid sequence of 53-
mer human EGF (hEGF) and 12-mer 22 showing sequence homology for the G, Y and E residues (highlighted 
in red). Peptide 22 also shows structural similarity (based on secondary structure prediction of 22) to this cyclic 
region of hEGF (residues 32–43). (c) Predicted secondary structure of peptide 22 using Chou and Fasman 
secondary structure prediction (CFSSP) server37,38. (d) 3D structure of a portion (residues 32–43) of hEGF 
derived from the crystal structure of full length hEGF (PDB code 1JL9)35. (e) Energy minimized structure of 
peptide 22 obtained using PEP-fold 2.043 and Swiss-Pdb Viewer 4.142. Side chains are not shown here for clarity.
www.nature.com/scientificreports/
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drug targeting. Targeted delivery of doxorubicin for the treatment of ovarian cancer was recently reported using 
peptide GE11 conjugated reversibly crosslinked polymersomes carrying doxorubicin39. These peptide GE11 con-
jugated polymersomes showed 2.5-fold higher accumulation in the tumor compared to liposomal doxorubicin, 
caused minimal side effects at high doses, and led to increased survival rate in SKOV3-tumor bearing mice39. The 
new analogues of peptide 1 (or GE11) such as peptides 22, 23, 26, and 27 could serve as superior ligands for the 
targeted delivery of therapeutics for cancer treatment.
experimental section
Materials. All solvents and chemicals including triisopropylsilane (TIPS), dichloromethane (DCM), dimethyl-
formamide (DMF), N-methylmorpholine (NMM), diethyl ether, ethanol, acetonitrile, trifluoroacetic acid (TFA) 
were obtained from Sigma-Aldrich (now Millipore Sigma, St. Louis, MO, USA). Piperidine (20%) was purchased 
from Protein Technology (AZ, Tucson, USA). CyQUANT and FITC dyes were obtained from Invitrogen (Eugene, 
Oregon, USA). Derivatized cellulose membranes were from Intavis (AG, Germany). Milli-Q system was used for 
ultrapure water. Media RPMI-1640 and Leibovitz’s L-15 were from American Type Culture Collection (ATCC, 
Manassas, VA, USA). DMEM, Step/Pen, Hank’s Balanced Salt Solution (HBSS), 0.05% trypsin/EDTA and horse 
serum were obtained from Gibco (USA) and Hyclone (Pittsburgh, PA, USA). Hydrocortisone was from Acros 
Organics (New Jersey, USA). Human recombinant EGF was obtained from Corning (New York, USA).
Peptide array syntheses were done on automated spot synthesizer ResPep SL apparatus (Intavis AG, 
Germany). Synthesis of soluble peptides was performed on automated peptide synthesizer Tribute from Protein 
Technologies (AZ, Tucson, USA). HPLC system used was Prominence-i Shimadzu (Kyoto, Japan). ChemiDoc™ 
XRS + system from Bio-Rad (California, USA) was used to record fluorescence intensity of spots on membranes. 
Cell uptake studies were carried out on BD FACSVerse Flow Cytometer (BD Biosciences, California, USA). Cells 
were counted using hemocytometer Neubauer Chamber. Peptide concentration was determined using Shimadzu 
BioSpec-nano Micro-volume UV-Vis Spectrophotometer (Shimadzu, Kyoto, Japan).
Cell Lines. Cell lines were purchased from ATCC and were treated as recommended by ATCC for unpacking, 
handling, and culturing. MCF-10A and MCF-12A were cultured in DMEM/F12 media containing all compo-
nents needed for growth media (Horse serum 5%, EGF 20 ng/mL, hydrocortisone 0.5/mL, insulin 10 µg/mL, Pen/
Strep 1%). The media used for these two cell lines are modified version of ATCC. For culturing MDA-MB-436, 
L15 media supplemented with 10 µg/mL insulin, 16 µg/mL glutathione and 10% FBS was used. MDA-MB-231 
and MDA-MB-468 were cultured in DMEM containing 10% FBS and 1% Pen/Strep. Except for MDA-MB-436, all 
cells were cultivated at 37 °C with 5% CO2. MDA-MB-436 cells were kept at 37 °C with 100% air. The conditions 
for cell culture for each of the cell lines are described in Supplementary Information Table S1.
Peptide Array Synthesis. Thirty peptide sequences in duplicates were synthesized on functionalized cel-
lulose membrane using fully automated ResPep SL peptide array synthesizer (Intavis, Germany) following pre-
vious procedure with some modifications (Fig. S2)40,41. Previously we used a semi-automatic AutoSpot (Intavis) 
synthesizer that required the fmoc deprotection with piperidine to be performed manually32. However, in the 
fully automated ResPep SL peptide array synthesizer all the steps for building the peptide chain are done by the 
robot. Briefly, the sequences of peptides were entered in robot software and 96 spot synthesis mode was selected 
for the library. The membrane was first immersed in DMF for an hour. It was then placed inside the holder of 
robot on a paper filter and was fixed with screws. The membrane was washed with ethanol few times and dried 
using vacuum to remove any bubbles below the membrane. Fmoc-peptide synthesis methodology with DIC and 
Oxyma pure as coupling reagent and racemization suppressor, respectively, was used. For each peptide spot, an 
80 μL aliquot of activated amino acid (0.5 M) was delivered on the membrane surface using a robotic syringe. 
After each amino acid was double coupled, capping of unreacted amino acids was done using acetic anhydride 
(3%) and subsequently Fmoc-deprotection was achieved using 20% piperidine. After the synthesis was complete, 
the membrane was removed from the synthesizer platform and was manually dipped in deprotection solution 
containing approximately 50% TFA (15 mL), DCM (15 mL), TIPS (900 µL) and water (600 µL), and was kept for 
3 h at room temperature32. The deprotection of the side-chain protecting groups was done using the same reaction 
conditions as originally developed. This procedure allowed complete removal of all side chain protections includ-
ing the side chain Pbf of Arg32. Thereafter the membrane was washed extensively in several steps with DCM, DMF 
and ethanol, respectively. Finally it was air dried and kept in sealed bag at −20 °C until use.
Peptide Array-Cell Binding Assay. For the binding assay, the peptide array was incubated with the cells 
in sequential steps as described previously32. Briefly peptide array membrane was dipped in ethanol for 30 s to 
remove any precipitation on it, followed by dipping in sterile PBS (pH 7.4) for another 30 min. The cells (75 × 103 
cells/mL) were seeded directly on the membrane in a sterile plate and incubated at 37 °C for 4 h. The unbound 
cells were washed out with sterile PBS (pH 7.4). Thereafter the membrane was placed in a sealed bag and trans-
ferred to −80 °C freezer for 2 h. Subsequently it was defrosted at room temperature and treated with CyQUANT 
solution. The CyQUANT concentration was optimized based on the manufacturer’s protocol and preliminary 
experiments. Membrane was incubated at 37 °C for 30 min with the dye. After washing with sterile PBS and air 
drying using blow dryer, the membrane was scanned using Bio-rad chemidoc imager with image lab software. 
The settings were adjusted based on the excitation (465 nm) and emission (535 nm) wavelengths of CyQUANT 
dye. Epi Blue was selected for the light source (455–485 nm) and filter number 4 (blue filter, 518–546 nm) was 
employed. The fluorescence intensity of cancer cells read using chemidoc imager was normalized using the 
non-cancer cell fluorescence intensity. Eventually relative fluorescence was assessed to select peptides with high 
affinity to cancer cells and low or minimal binding to normal cells.
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Synthesis of FITC Labeled Peptides. Six peptides, including peptide 1 (GE11), peptide 4 (p160) and 
analogues 22, 23, 26 and 27, were selected for further studies. These peptides were synthesized following Fmoc 
solid phase peptide synthesis (Fmoc-SPPS) on preloaded Fmoc-isoleucine or leucine Wang resin (0.1 mmol 
scale) using automated peptide synthesizer (Tribute, Protein Technology) as reported previously. Preloaded 
Fmoc-isoleucine or leucine Wang resin (320 mg, 0.1 mmol) was added to the glass reaction vessel (RV) and the 
resin was allowed to swell in DMF under nitrogen with mechanical shaking for 30 min. All amino acids (3 equiv 
in 3 mL DMF) were coupled in sequence using HCTU (2.5 equiv) and NMM (1.2 equiv) for each coupling. Fmoc 
was removed by 20% piperidine in DMF. β-alanine was added at the N-terminal of each peptide sequence as a 
spacer before FITC coupling. FITC (0.3 mmol) in DMF (3 mL) with DIPEA (0.15 mmol) was added to the resin, 
and the mixture was incubated in the dark for 20 h. Small amount of the resin was used for a test cleavage using 
cleavage cocktail (1 mL) of trifluoroacetic acid (TFA)/triisoproylsilane/ ultra-pure water (95:2.5:2.5) for 2 hours. 
Cold diethyl ether (Et2O, 5 mL) was added to the filtered resin followed by centrifugation for 10 min in order to 
precipitate and collect the crude peptide. The successful conjugation was confirmed using MALDI-TOF and 
RP-HPLC of the test cleavage. Cleavage of FITC-peptides from the entire resin was done manually using same 
cleavage cocktail (10 mL) as described above. The peptides were precipitated using cold diethyl ether (20 mL). All 
peptides were characterized using MALDI-TOF mass spectrometry and RP-HPLC (Table S2 and Figs S3–S8). 
Purification was done using semi-preparative C18 Vydac column RP-HPLC.
In vitro Cellular Uptake. Fluorescence-activated cell-sorting (FACS) analysis was used to check the uptake 
of the FITC-peptides. The stock solution for the FITC-peptides (100 μM) was prepared by dissolving the peptides 
in sterile water/10% DMSO. MDA-MB-231, MDA-MB-468 and MDA-MB-436 cells were seeded in 6-well plates 
with 106/105 cells/well containing 3 mL media and the plates were incubated at 37 °C overnight. The following day, 
the media was replaced with fresh FBS free media (1 mL) containing FITC-labeled peptide (1 µM), and further 
incubated at 37 °C for 30 min. Thereafter the media was removed and the cells were washed with cold PBS to 
remove any remaining peptide. Adequate trypsin was added to each well followed by 3–5 min incubation at 37 °C. 
Trypsin was immediately neutralized by adding media and the cell suspension was transferred into centrifuge 
tubes. The cells were separated and washed twice with FACS sheath fluid. The control cells were treated similarly 
but without peptide. Two wells were assigned for each peptide and each well sample was read twice in FACS 
machine. The experiment was repeated once. MFI represents the average of all wells for each peptide.
In addition, MDA-MB-231 cells (105) were incubated with varying concentration of peptide FITC-22 
(0–6 μM). The resulting samples were treated as above, and the experiment was repeated. The fluorescence inten-
sity of the FITC peptide-cell complex was plotted against peptide concentration. Finally, competition experiment 
was done in the presence of EGF (20 µM, 20x excess) or unlabeled peptide 1 (100 µM, 100 times more) as compet-
itors. Protein EGF or unlabeled peptide was added to the wells first, followed by addition of FITC-labeled peptide 
1 or peptide 22 and the plate was incubated for 30 min. Control group was treated with media alone containing 
~5% DMSO. Each group was done in duplicate and the experiment was repeated once.
Structure Prediction Methods. The Chou and Fasman secondary structure prediction (CFSSP) server was 
used to obtain predicted secondary structures for peptide 2237,38. The three dimensional structure of a portion of 
EGF (12 residues, 32–43) was created using the PBD structure of EGF protein (PDB code 1JL9)35 and Swiss-Pdb 
Viewer 4.142. A PDB structure for peptide 22 was generated using the de novo peptide structure prediction soft-
ware PEP-fold 2.043. The structure was further refined using the “magic fit” module and energy minimization of 
Swiss-Pdb Viewer 4.142.
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